RET (G691S)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.G691S
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pralsetinib | 98.6% | 1.4% | 93.43 |
| 2 | Tenalisib | 98.2% | 1.8% | 97.98 |
| 3 | Alpelisib | 98.2% | 1.8% | 97.22 |
| 4 | Fedratinib | 97.2% | 2.8% | 96.21 |
| 5 | Entrectinib | 96.8% | 3.2% | 93.69 |
| 6 | Nintedanib | 96.7% | 3.3% | 90.23 |
| 7 | Ponatinib | 96.0% | 4.0% | 78.23 |
| 8 | Gilteritinib | 94.3% | 5.7% | 88.97 |
| 9 | Lenvatinib | 93.6% | 6.4% | 97.74 |
| 10 | Alectinib | 93.6% | 6.4% | 95.49 |
| 11 | Regorafenib | 93.1% | 6.9% | 95.99 |
| 12 | Selpercatinib | 92.7% | 7.3% | 96.72 |
| 13 | Futibatinib | 92.3% | 7.7% | 98.48 |
| 14 | Cabozantinib | 91.7% | 8.3% | 92.73 |
| 15 | Sorafenib | 91.5% | 8.5% | 96.72 |
| 16 | Quizartinib | 91.5% | 8.6% | 99.50 |
| 17 | Sunitinib | 90.6% | 9.4% | 91.73 |
| 18 | Tivozanib | 90.1% | 9.9% | 92.42 |
| 19 | Ripretinib | 89.6% | 10.4% | 92.95 |
| 20 | Brigatinib | 89.4% | 10.6% | 82.96 |
| 21 | Vandetanib | 88.3% | 11.7% | 95.74 |
| 22 | Apatinib | 87.9% | 12.1% | 97.73 |
| 23 | Erdafitinib | 86.2% | 13.8% | 95.71 |
| 24 | Repotrectinib | 82.3% | 17.7% | 84.21 |
| 25 | Avapritinib | 77.9% | 22.1% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pralsetinib | 98.6% | 100.0% | -1.4% |
| Tenalisib | 98.2% | 98.5% | -0.3% |
| Alpelisib | 98.2% | 99.6% | -1.5% |
| Fedratinib | 97.2% | 99.9% | -2.6% |
| Entrectinib | 96.8% | 99.6% | -2.8% |
| Nintedanib | 96.7% | 100.0% | -3.3% |
| Ponatinib | 96.0% | 100.0% | -4.0% |
| Gilteritinib | 94.3% | 100.0% | -5.7% |
| Lenvatinib | 93.6% | 98.8% | -5.2% |
| Alectinib | 93.6% | 97.8% | -4.2% |
| Regorafenib | 93.1% | 98.7% | -5.7% |
| Selpercatinib | 92.7% | 100.0% | -7.3% |
| Futibatinib | 92.3% | 97.7% | -5.3% |
| Cabozantinib | 91.7% | 97.5% | -5.9% |
| Sorafenib | 91.5% | 94.0% | -2.5% |
| Quizartinib | 91.5% | — | — |
| Sunitinib | 90.6% | 97.2% | -6.6% |
| Tivozanib | 90.1% | 99.7% | -9.7% |
| Ripretinib | 89.6% | — | — |
| Brigatinib | 89.4% | 94.9% | -5.5% |
| Vandetanib | 88.3% | 98.6% | -10.3% |
| Apatinib | 87.9% | — | — |
| Erdafitinib | 86.2% | 94.7% | -8.5% |
| Repotrectinib | 82.3% | — | — |
| Avapritinib | 77.9% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_breast | Breast | ref |
| haemangioblastoma_soft_tissue | Soft Tissue | ref |
| meningioma_meninges | Brain/CNS | ref |
| carcinoma_lung | Lung | ref |
| carcinoma_large_intestine | Large Intestine | ref |
| pheochromocytoma_adrenal_gland | Adrenal | ref |
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| BRCA-KR | Breast | ref |
| LAML-KR | Blood/Lymphatic System | ref |
| LUSC-KR | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.2ms